Results 261 to 270 of about 1,428,732 (361)

Hepatitis Vaccines: Recent Advances and Challenges. [PDF]

Vaccines (Basel)
Lu M, Liu Y, Li L, Liu X, Wu B, Wu Y.
europepmc   +1 more source

Conformational Trajectory of the Molecular Chameleon Grazoprevir from Formulation to Target‐Bound

Chemistry – A European Journal, EarlyView.
ABSTRACT Macrocycles represent a promising class of beyond‐rule‐of‐5 (bRo5) therapeutics, capable of targeting proteins traditionally considered undruggable by conventional small molecules. Macrocycles exhibit intrinsic flexibility and often display a “chameleon‐like” ability to adapt to their environment, thereby enhancing their oral bioavailability ...
Lianne H. E. Wieske, Guanhong Bu, Máté Erdélyi, Jan Kihlberg, Tamir Gonen, Emma Rova Danelius   +5 more
wiley   +1 more source

Vaccine coverage, antibodies against measles, mumps, rubella, hepatitis B in inflammatory bowel disease and juvenile idiopathic arthritis children. [PDF]

World J Clin Pediatr
Makarova E, Goleva O, Gabrusskaya T, Lubimova N, Ulanova N, Volkova N, Shilova E, Revnova M, Kharit S, Kostik M.   +9 more
europepmc   +1 more source

Autoimmune Hepatitis.

Internal Medicine, 1993
M, Zeniya, G, Toda
openaire   +4 more sources

Fluorescent Dyes for Probing Intracellular and Subcellular Polarity

Chemistry–Methods, EarlyView.
Fluorescent probes are crucial tools for measuring cellular microenvironment polarity, a parameter that influences physiological organelle function and diseases such as cancer. This text details the probes' physicochemical principles, intracellular targeting strategies, and key photophysical parameters for polarity estimation.
M. Carmen Gonzalez‐Garcia, Maria J. Ruedas‐Rama, Juan A. González‐Vera, Emilio Garcia‐Fernandez, Angel Orte   +4 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye   +6 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

A Phase 1, Randomized, Open‐Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bepirovirsen, an antisense oligonucleotide in development for the treatment of chronic hepatitis B virus (HBV) infection, is administered from glass vials as a subcutaneous (SC) injection by healthcare professionals (HCPs). A ready‐to‐use prefilled syringe (PFS) assembled with a safety syringe device (SSD) has been developed to make ...
Amir S. Youssef, Poonam Shah, Maxwell Hu, Helene Plein, Abhishek Roy, Ravi Sharma, Sarah Mole, Magdalena Blazejczyk, Wendy Cross, Brian Spears, Samuel Pak, Rejbinder Kaur, Robert Elston, Dickens Theodore, Marjan Hezareh, Ahmed Nader   +15 more
wiley   +1 more source

Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Votoplam is a novel, orally bioavailable, small molecule HTT gene splicing modifier that is being developed for the treatment of Huntington's disease. This was a single dose, open‐label, two‐period, crossover food effect study that evaluated the effect of high‐ and low‐fat meals on 20 mg votoplam in healthy participants. There was a washout of
Lucy Lee, Amy‐Lee Richards, Nageswara Reddy, Brian Beers, Lee Golden, Ronald Kong   +5 more
wiley   +1 more source

Expression of mutant TIE2 p.L914F during mouse development causes embryonic lethality and defects in vascular remodeling

Developmental Dynamics, EarlyView.
Abstract Background Sporadic venous malformation (VM) is associated with the hyperactivating p.L914F mutation in TIE2, a receptor tyrosine kinase essential for vascular development. This mutation is not found in hereditary VM, suggesting incompatibility with life when expressed during early vascular development.
Lindsay J. Bischoff, Sandra Schrenk, Kara Soroko, Chhiring Sherpa, Ashok Arasu, Damien Reynaud, Elisa Boscolo   +6 more
wiley   +1 more source